William Todd
Internal Medicine · Byrdstown, TNNPI 1558534909
Payments from drug & device makers
Across 182 payments — averaging $17.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$911
- Gilead$301
- Novartis$253
- AbbVie$245
- Amgen$195
- Lilly USA, LLC$170
- plus $1K from 24 others
What the payments were for
- Food & beverage$3,08499%
- Education$401%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 53 | $911 |
| Gilead | 18 | $301 |
| Novartis | 14 | $253 |
| AbbVie(2 entities) | 15 | $245 |
| Amgen | 11 | $195 |
| Lilly USA, LLC | 11 | $170 |
| Merck | 8 | $124 |
| Alkermes, Inc. | 5 | $101 |
| Grifols USA, LLC | 5 | $85 |
| Sanofi Pasteur Inc. | 4 | $72 |
| Mayne Pharma Commercial LLC | 4 | $71 |
| Johnson & Johnson | 5 | $71 |
| Astellas Pharma US Inc | 3 | $63 |
| Sanofi-aventis U.S. LLC | 3 | $59 |
| Insmed, Inc. | 3 | $55 |
| GSK | 3 | $44 |
| Eisai Inc. | 2 | $36 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $34 |
| Amarin Pharma, Inc. | 2 | $33 |
| Sunovion Pharmaceuticals Inc. | 2 | $25 |
| Daiichi Sankyo Inc. | 1 | $24 |
| Indivior Inc. | 1 | $23 |
| Otsuka America Pharmaceutical, Inc. | 1 | $21 |
| Ferring Pharmaceuticals Inc. | 1 | $19 |
| Corcept Therapeutics | 1 | $18 |
| Seqirus USA Inc | 1 | $16 |
| Mylan Specialty L.p. | 1 | $16 |
| Ironshore Pharmaceuticals Inc. | 1 | $14 |
| AstraZeneca | 1 | $13 |
| Romark Laboratories, LC | 1 | $11 |
How this compares
$3,125 in reported general payments places this provider in the 80th percentile of 2,216 internal medicine providers in Tennessee.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 56 | $29,340 |
| OzempicSemaglutide | 25 | $28,615 |
| TrulicityDulaglutide | 24 | $23,017 |
| RybelsusSemaglutide | 11 | $15,848 |
| CeftriaxoneCeftriaxone Sodium | 32 | $15,006 |
| Doxycycline Hyclate | 72 | $6,903 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 12 | $5,631 |
| Pantoprazole Sodium | 94 | $3,242 |
| Ondansetron Hcl | 16 | $3,119 |
| Humalog Kwikpen U-100Insulin Lispro | 15 | $2,798 |
| Hydroxychloroquine Sulfate | 51 | $2,748 |
| Solifenacin Succinate | 17 | $2,560 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $1,939 |
| Potassium Chloride | 82 | $1,922 |
| Famotidine | 59 | $1,901 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $911 | $44,46336 claims |
| Lilly USA, LLCTrulicity, Olanzapine | $170 | $23,97944 claims |
| GSKAnoro Ellipta | $44 | $5,63112 claims |
| AbbVieSynthroid | $245 | $85513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,216 internal medicine providers in Tennessee.
Other internal medicine in Byrdstown
- Mark McKenzieChattanooga$11.9M
- Bernard GrunstraBristol$6.4M
- Jewel WhiteKingsport$5.7M
- Judith WhiteKingsport$5.6M
- Obadias MarquezOoltewah$2.8M
- Amanda Moore MillerKnoxville$2.3M
- Rick WhilesBristol$1.5M
- John AndersonNashville$1.5M
- David MorinKingsport$1.4M
- John KirbyJefferson City$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.